← Back to patent-cliff list
CAS 1346245-03-1
2-(1-methyl-1H-pyrazol-4-yl)-7-nitroquinoxaline
Codes：ERDA-003、ERDA-012
Application context (from source-drug indications)
尿路上皮癌厄达替尼泌尿系肿瘤厄达替尼
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 厄达替尼Erdafitinib | Tier C — Watch / trade | 2030 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
6-bromoquinoxaline→1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole→2-(1-methyl-1H-pyrazol-4-yl)-7-nitroquinoxaline→7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline→3,5-dimethoxyaniline→N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine→(2-bromoethoxy)(tert-butyl)dimethylsilane→N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine→2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethanol→2-((3,5-dimethoxyphenyl)(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)amino)ethyl methanesulfonate→Erdafitinib
2-(1-methyl-1H-pyrazol-4-yl)-7-nitroquinoxaline→2-chloro-7-nitroquinoxaline→ERDA-012→3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine→1-bromo-3,5-dimethoxybenzene→N-(3,5-dimethoxyphenyl)-3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-amine→N-(2-chloroethyl)propan-2-amine hydrochloride→Erdafitinib
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.